Calpain-10 expression is elevated in pancreatic islets from patients with type 2 diabetes.
BACKGROUND
Calpain-10 was the first gene to be identified influencing the risk of type 2 diabetes (T2D) by positioning cloning. Studies in beta-cell lines and rodent islets suggest that calpain-10 may act as a regulator of insulin secretion. However, its role in human pancreatic islets remains unclear. The aim of this study was to examine if calpain-10 expression is altered in islets from patients with T2D and if the transcript level correlates with insulin release. We also tested if polymorphisms in the CAPN10 gene are associated with gene expression and insulin secretion in vitro.


RESULTS
Calpain-10 mRNA expression was analysed in human pancreatic islets from 34 non-diabetic and 10 T2D multi-organ donors. CAPN10 SNP-43 and SNP-44 were genotyped and related to gene expression and insulin release in response to glucose, arginine and glibenclamide. The mRNA level of calpain-10 was elevated by 64% in pancreatic islets from patients with T2D compared with non-diabetic donors (P = 0.01). Moreover, the calpain-10 expression correlated positively with arginine-stimulated insulin release in islets from non-diabetic donors (r = 0.45, P = 0.015). However, this correlation was lost in islets from patients with T2D (r = 0.09; P = 0.8). The G/G variant of SNP-43 was associated with reduced insulin release in response to glucose (P</=0.04) in non-diabetic donors.


CONCLUSIONS
While calpain-10 expression correlates with insulin release in non-diabetic human islets, this correlation is lost in T2D suggesting that a stimulatory effect of calpain-10 could be lost in patients with T2D.
Ling
Charlotte
C
Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Clinical Research Centre (CRC), Malmö, Sweden. charlotte.ling@med.lu.se
Groop
Leif
L
Guerra
Silvia Del
SD
Lupi
Roberto
R
D001120:Arginine / Q000008:administration & dosage; D001483:Base Sequence; D002154:Calpain / Q000235:genetics / Q000378:metabolism*; D016022:Case-Control Studies; D017931:DNA Primers; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology*; D005947:Glucose / Q000008:administration & dosage; D005905:Glyburide / Q000008:administration & dosage; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000201:enzymology*; D010190:Pancreatic Neoplasms / Q000201:enzymology*; D020641:Polymorphism, Single Nucleotide; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
D017931:DNA Primers; D007328:Insulin; D012333:RNA, Messenger; D001120:Arginine; D002154:Calpain; C415197:calpain 10; D005947:Glucose; D005905:Glyburide
Diabetes. 2001 Sep;50(9):2013-20
11522666
Nat Rev Genet. 2007 Sep;8(9):657-62
17703236
Diabetes. 2005 Mar;54(3):727-35
15734849
Diabetologia. 2007 Dec;50(12):2486-94
17906960
Biochem Biophys Res Commun. 2007 Jan 19;352(3):650-5
17150188
Diabetes. 2005 Oct;54(10):3015-20
16186407
J Clin Endocrinol Metab. 2004 Jul;89(7):3601-5
15240652
J Biol Chem. 2004 Jun 4;279(23):24794-802
15044459
Physiol Rev. 1991 Jul;71(3):813-47
2057527
Metabolism. 2003 May;52(5):528-34
12759879
Mol Genet Metab. 2006 Sep-Oct;89(1-2):174-84
16837224
Nat Genet. 2000 Oct;26(2):163-75
11017071
Diabetes. 2004 Feb;53 Suppl 1:S19-25
14749261
Diabetes. 2001 Sep;50(9):2161-3
11522685
J Clin Invest. 2000 Oct;106(7):R69-73
11018080
Diabetes. 2002 Aug;51(8):2658-64
12145185
Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E313-21
15784646
Diabetes. 2002 Dec;51(12):3561-7
12453914
Mol Endocrinol. 2005 Jan;19(1):213-24
15471947
Am J Hum Genet. 2001 Sep;69(3):544-52
11481585
Diabetologia. 2008 Apr;51(4):615-22
18270681
Diabetologia. 2004 May;47(5):782-93
15114470